Second-Generation Antihistamine Drugs May Improve Outcomes for Cancer Patients Receiving Immunotherapy – Genetic Engineering & Biotechnology News

Studies headed by scientists at the University of Texas MD Anderson Cancer Center suggest that an over-the-counter, second-generation antihistamine drug could improve outcomes for cancer patients who are treated using anti-PD-1/PD-L1 checkpoint inhibitors…

Click here to view the original article.